24小时热门版块排行榜    

查看: 956  |  回复: 4
【奖励】 本帖被评价3次,作者_菜菜子增加金币 2.4
当前只显示满足指定条件的回帖,点击这里查看本话题的所有回帖

_菜菜子

新虫 (初入文坛)


[资源] 肝癌细胞中的循环肿瘤生物标记物研究

Circulating biomarkers in hepatocellular carcinoma
Abstract
Purpose Our aims are to determine levels of circulating cellular and protein biomarkers in hepatocellular carcinoma (HCC) patients and to analyse any relationships with clinical parameters.
Methods Fifty-four consenting patients were recruited.Circulating tumour cells (CTCs) were enumerated (by Cell-Search) and characterised via filtration [by isolation by size of epithelial tumour cells (ISET)] with downstream immunohistochemistry (IHC). Glypican-3 (GPC3) expression in tumour biopsies and CTCs (by IHC) was compared, and levels of circulating caspase-cleaved and full-length cytokeratin 18 (CK18, measured using M30 and M65 ELISAs) were examined as a putative prognostic factor and marker of tumour burden.
Results CTCs were identified in 14 out of 50 (28 %) patients by CellSearch and in 19 out of 19 (100 %) patients by ISET. The presence of GPC3-positive CTCs by ISET was 100 % concordant with the presence of GPC3-positive cells in the original tumour (n = 5). No statistically significant correlations were observed between CTC number and clinical characteristics, although trends were noted between CTC subtypes, Child–Pugh score and tumour node metastasis stage. Serum M30 and M65 levels (as continuous variables) significantly correlated with overall survival (OS)in a univariate analysis (p = 0.003 and p < 0.001, respectively);M65 levels remained statistically significant in a multivariate analysis (p = 0.029).
Conclusions This is the first study to detect GPC3-positive CTCs in HCC, important for drug development with this target. The significant association of circulating CK18 with OS in HCC further exemplifies the utility of circulating biomarkers in cancer.

Materials and methods
Patients
Sequential patients with a diagnosis of HCC were recruited to the study at two centres: The Christie NHS Foundation Trust, Manchester, UK, and North Manchester General Hospital, Manchester, UK. Patients either had no antitumour therapy within 4 weeks, or had evidence of progressive disease if prior therapy had been received and were awaiting further therapy. Clinical data collected included age, sex, Child–Pugh score, serum alpha-fetoprotein (AFP), performance status (PST), viral status, radiological extent of disease, time to progression and overall survival (OS). In addition, treatment history, tumour node metastasis (TNM) staging, Okuda stage, Barcelona stage (BCLC) and aetiological risk factors were collated.

Samples
After informed consent, a single blood draw of up to 30 ml was taken for biomarker analysis at baseline (defined as 4 weeks after any previous treatment, or evidence of progressive disease if therapy had been received and awaiting further therapy or supportive care only). Serum was isolated from 10 ml coagulated whole blood (collected in serum gel tubes) for analysis of the levels of full-length and/or caspase-3-cleaved cytokeratin 18 (CK18) using the M65 and M30 ELISAs, respectively; 10 ml blood was sampled into a CellSave tube (Veridex) for CTC enumeration by CellSearch, and wherever possible 10 ml (EDTA ) was sampled for analysis using the filtration-based ISET device[8]. Tumour biopsies were also obtained from 12 patients in order to compare GPC3 expression levels in CTCs with tumour at the time of diagnosis.

Cell lines and antibodies
SK-HEP-1 HCC cells (GPC3-negative) that had been transfected with human GPC3 cDNA were used as positive controls:SK-03 was a high expresser of GPC3, and SK-PCA13a had intermediate expression of GPC3 [9]. These cell lines were provided by Chugai Pharmaceutical Co., Ltd. Human Vascular Endothelial Cells (HUVEC) were used as endothelial cell controls to allow exclusion of circulating endothelial cells (CECs) in the CTC assay following CTC enrichment by ISET. All cell lines were cultured according to standard protocols. A mouse monoclonal antibody against GPC3 (mGC33) for immunohistochemical (IHC) analysis of tissue biopsies and of CTCs captured on ISET filters was provided by Chugai Pharmaceutical Co., Ltd. [10]. The cell lines and mGC33 antibody were used to validate GPC3 immunohistochemical assays in tissue and in cells.

Enumeration and assessment of GPC3 status of CTCs
CTCs were enumerated using the CellSearch platform in blood samples from 50 patients. The CellSearch methodology has been described previously [11, 12] and is based on the immunomagnetic capture of epithelial adhesion molecule (EpCAM) positive cells followed by immunophenotyping of cytokeratin, DAPI and CD45 in cells isolated from a 7.5-ml blood volume. CTCs are classed as CK+,DAPI+ and CD45?. In order to establish GPC3 expression in CTCs, an AF-488-conjugated antibody against GPC3 (mGC33) was also added to the samples in the fourth channel of the CellSearch at a concentration of 4 μg/test. The exposure time for signal detection of GPC3 was 0.4 s. This enabled the enumeration of GPC3-positive CTCs as a proportion of the total CTC count in 7.5 ml blood.
回复此楼

» 本帖附件资源列表

  • 欢迎监督和反馈:小木虫仅提供交流平台,不对该内容负责。
    本内容由用户自主发布,如果其内容涉及到知识产权问题,其责任在于用户本人,如对版权有异议,请联系邮箱:xiaomuchong@tal.com
  • 附件 1 : 肝癌细胞中的循环生物标记物研究_-铂悦仪器-2015.pdf
  • 2016-02-01 11:44:00, 2.26 M

» 猜你喜欢

» 本主题相关价值贴推荐,对您同样有帮助:

已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

ally7161

木虫 (小有名气)


5楼2016-03-23 12:39:14
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
查看全部 5 个回答
简单回复
silongs4楼
2016-03-23 11:41   回复  
五星好评  顶一下,感谢分享!
2016-02-02 15:40   回复  
五星好评  顶一下,感谢分享!
2016-02-01 17:22   回复  
五星好评  顶一下,感谢分享!
☆ 无星级 ★ 一星级 ★★★ 三星级 ★★★★★ 五星级
普通表情 高级回复 (可上传附件)
最具人气热帖推荐 [查看全部] 作者 回/看 最后发表
[基金申请] 时间戳变了,能看出什么问题? +14 基诺咪客 2026-08-17 18/900 2026-08-20 12:13 by saint2016
[基金申请] 重要消息,中午系统在维护 +11 yuleib84 2026-08-18 12/600 2026-08-20 11:09 by xskun
[基金申请] 哪位老哥知道今年的国自然具体哪一天放榜? +16 Ldrop2023 2026-08-13 20/1000 2026-08-20 11:07 by xskun
[基金申请] 言之凿凿,8月21号(明天)放榜 +12 医学老男孩 2026-08-20 14/700 2026-08-20 10:53 by ran2233
[基金申请] 今天基金会出结果吗?20260819 +14 kkkl_v 2026-08-19 15/750 2026-08-20 08:21 by sunzitan
[基金申请] filecode,4个jtjc了 +11 ziyangfang 2026-08-19 13/650 2026-08-19 21:28 by aasahr
[教师之家] 为什么余额宝的年化利率越来越低?主要原因有哪些? +5 瞬息宇宙 2026-08-15 5/250 2026-08-19 20:23 by super2002521
[基金申请] 今天放榜没戏了吧 +4 yuleib84 2026-08-19 5/250 2026-08-19 19:52 by hhs666
[基金申请] filecode=后面第一个是大写字母 +10 wangze12014 2026-08-14 12/600 2026-08-19 16:56 by 苦难博士
[基金申请] 2027广东省杰青 +4 奶牛小黑 2026-08-15 10/500 2026-08-19 11:02 by wanfengnew
[基金申请] 朋友圈看到的 +6 wangzilk 2026-08-18 8/400 2026-08-19 10:55 by Haru815
[基金申请] 快农历七夕节了,轻松一下,男人悄悄话,女施主请不要进来。 +6 Tide man 2026-08-14 7/350 2026-08-19 09:56 by ZJTJZ
[基金申请] 什么时候开奖? +6 CrisMessi 2026-08-18 6/300 2026-08-19 08:06 by Equinoxhua
[基金申请] 明天放榜? +5 Shxjjxjkx 2026-08-18 5/250 2026-08-18 18:14 by -大大大大大-
[基金申请] 时间戳又变了8-15 +14 archvillain 2026-08-15 26/1300 2026-08-18 13:37 by phantomgost
[基金申请] 今天维护系统维护 祝所有人 高中 +8 gjjjzhong 2026-08-18 9/450 2026-08-18 13:01 by 家与远方
[基金申请] 93BebMhtakh前后11位开头都是大写 +4 且听虎啸 2026-08-17 5/250 2026-08-18 00:49 by 蔡棒棒菂
[基金申请] 感觉是下周放榜了 +6 angus9576 2026-08-17 11/550 2026-08-17 23:57 by angus9576
[基金申请] 今天系统多次维护,明天很可能放榜! +8 zju2000 2026-08-16 9/450 2026-08-17 12:20 by lmz0216
[基金申请] 各位道友,我要去昆明玩几天,回来见。 +7 Tide man 2026-08-14 8/400 2026-08-15 01:11 by arzu_hma
信息提示
请填处理意见